Levodopa modulates small-world architecture of functional brain networks in Parkinson’s disease

Movement Disorders

Volumn 31, Issue 11, 2016, Pages 1676-1684

  Berman, Brian D ^a,b   Smucny, Jason ^a   Wylie, Korey P ^a   Shelton, Erika ^a   Kronberg, Eugene ^a   Leehey, Maureen ^a   Tregellas, Jason R ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

graph theory; levodopa; Parkinson disease; resting state fMRI

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; ANTIPARKINSON AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; MONTREAL COGNITIVE ASSESSMENT; NERVE CELL NETWORK; PARKINSON DISEASE; PRIORITY JOURNAL; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; BRAIN; CONNECTOME; DIAGNOSTIC IMAGING; DRUG EFFECTS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

AGED; ANTIPARKINSON AGENTS; BRAIN; CONNECTOME; FEMALE; HUMANS; LEVODOPA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE NET; PARKINSON DISEASE;

EID: 84989235553     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26713     Document Type: Article

References (47)

1. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia Nigra. Arch Neurol 2006;63(4):584–588.
2. Tessitore A, Giordano A, De Micco R, Russo A, Tedeschi G. Sensorimotor connectivity in Parkinson's disease: the role of functional neuroimaging. Front Neurol 2014;5:180.
3. Prodoehl J, Burciu RG, Vaillancourt DE. Resting state functional magnetic resonance imaging in Parkinson's disease. Curr Neurol Neurosci Rep 2014;14(6):448.
4. Poston K, Eidelberg D. Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage 2012;62(4):2261–2270.
5. Reijneveld JC, Ponten SC, Berendse HW, Stam CJ. The application of graph theoretical analysis to complex networks in the brain. Clin Neurophysiol 2007;118(11):2317–2331.
6. Stam CJ, van Straaten EC. The organization of physiological brain networks. Clin Neurophysiol 2012;123(6):1067–1087.
7. Bullmore E, Sporns O. The economy of brain network organization. Nat Rev Neurosci 2012;13(5):336–349.
8. Latora V, Marchiori M. Efficient behavior of small-world networks. Physical review letters 2001;87(19):198701.
9. Skidmore F, Korenkevych D, Liu Y, He G, Bullmore E, Pardalos PM. Connectivity brain networks based on wavelet correlation analysis in Parkinson fMRI data. Neurosci Lett 2011;499(1):47–51.
10. Gottlich M, Munte TF, Heldmann M, Kasten M, Hagenah J, Kramer UM. Altered resting state brain networks in Parkinson's disease. PLoS One 2013;8(10):e77336.
11. Tinaz S, Lauro P, Hallett M, Horovitz SG. Deficits in task-set maintenance and execution networks in Parkinson's disease. Brain Struct Funct 2016;221(3):1413–1425.
12. Zhang D, Liu X, Chen J, Liu B. Distinguishing patients with Parkinson's disease subtypes from normal controls based on functional network regional efficiencies. PLoS One 2014;9(12):e115131.
13. Carbonell F, Nagano-Saito A, Leyton M, et al. Dopamine precursor depletion impairs structure and efficiency of resting state brain functional networks. Neuropharmacology 2014;84:90–100.
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical-diagnosis of idiopathic Parkinson's disease - A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181–184.
15. Damian AM, Jacobson SA, Hentz JG, et al. The Montreal Cognitive Assessment and the Mini-Mental State Examination as Screening Instruments for Cognitive Impairment: Item Analyses and Threshold Scores. Dementia Geriatr Cogn Disord 2011;31(2):126–131.
16. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Mov Disord 2008;23(15):2129–2170.
17. Power JD, Cohen AL, Nelson SM, et al. Functional network organization of the human brain. Neuron 2011;72(4):665–678.
18. Power J, Barnes K, Snyder A, Schlaggar B, Petersen S. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012;59(3):2142–2154.
19. Zhang T, Wang J, Yang Y, et al. Abnormal small-world architecture of top-down control networks in obsessive-compulsive disorder. J Psychiatry Neurosci 2011;36(1):23–31.
20. Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. PLoS Comput Biol 2007;3(2):174–183.
21. Bullmore ET, Bassett DS. Brain graphs: graphical models of the human brain connectome. Annu Rev Clin Psychol 2011;7:113–140.
22. Humphries MD, Gurney K, Prescott TJ. The brainstem reticular formation is a small-world, not scale-free, network. Proc Biol Sci 2006;273(1585):503–511.
23. Kaiser M, Hilgetag CC. Nonoptimal component placement, but short processing paths, due to long-distance projections in neural systems. PLoS Comput Biol 2006;2(7):e95.
24. Wylie KP, Rojas DC, Tanabe J, Martin LF, Tregellas JR. Nicotine increases brain functional network efficiency. Neuroimage 2012;63(1):73–80.
25. Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage 2010;52(3):1059–1069.
26. Kelly C, de Zubicaray G, Di Martino A, et al. L-Dopa Modulates Functional Connectivity in Striatal Cognitive and Motor Networks: A Double-Blind Placebo-Controlled Study. J Neurosci 2009;29(22):7364–7378.
27. Baik K, Cha J, Ham J, et al. Dopaminergic modulation of resting-state functional connectivity in de novo patients with Parkinson's disease. Hum Brain Mapp 2014;35(11):5431–5441.
28. Poletti M, De Rosa A, Bonuccelli U. Affective symptoms and cognitive functions in Parkinson's disease J Neurol Sci 2012;317(1-2):97–102.
29. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson's disease dementia: a neural networks perspective. Brain 2015;138(Pt 6):1454–1476.
30. Wen MC, Ng SY, Heng HS, et al. Neural substrates of excessive daytime sleepiness in early drug naive Parkinson's disease: A resting state functional MRI study. Parkinsonism Relat Disord 2016.
31. Yoo K, Chung SJ, Kim HS, et al. Neural substrates of motor and non-motor symptoms in Parkinson's disease: a resting FMRI study. PLoS One 2015;10(4):e0125455.
32. Bullmore E, Fadili J, Maxim V, et al. Wavelets and functional magnetic resonance imaging of the human brain. Neuroimage 2004;23(Suppl 1):S234–S249.
33. Yao Z, Zhang Y, Lin L, et al. Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. PLoS Comput Biol 2010;6(11):e1001006.
34. Stam CJ, Jones BF, Nolte G, Breakspear M, Scheltens P. Small-world networks and functional connectivity in Alzheimer's disease. Cereb Cortex 2007;17(1):92–99.
35. He Y, Chen Z, Evans A. Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer's disease. J Neurosci 2008;28(18):4756–4766.
36. Olde Dubbelink KT, Hillebrand A, Stoffers D, et al. Disrupted brain network topology in Parkinson's disease: a longitudinal magnetoencephalography study. Brain 2014;137(Pt 1):197–207.
37. Ginestet CE, Nichols TE, Bullmore ET, Simmons A. Brain network analysis: separating cost from topology using cost-integration. PLoS One 2011;6(7):e21570.
38. Kitzbichler MG, Henson RN, Smith ML, Nathan PJ, Bullmore ET. Cognitive effort drives workspace configuration of human brain functional networks. J Neurosci 2011;31(22):8259–8270.
39. Watts DJ, Strogatz SH. Collective dynamics of ‘small-world’ networks. Nature 1998;393(6684):440–442.
40. Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci 2011;15(10):483–506.
41. Putcha D, Ross RS, Cronin-Golomb A, Janes AC, Stern CE. Altered intrinsic functional coupling between core neurocognitive networks in Parkinson's disease. Neuroimage Clin 2015;7:449–455.
42. Di X, Biswal BB. Modulatory interactions between the default mode network and task positive networks in resting-state. PeerJ 2014;2:e367.
43. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13(7):266–271.
44. Hisahara S, Shimohama S. Dopamine receptors and Parkinson's disease. Int J Med Chem 2011;2011:403039.
45. Birn RM, Molloy EK, Patriat R, et al. The effect of scan length on the reliability of resting-state fMRI connectivity estimates. Neuroimage 2013;83:550–558.
46. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43(2):367–371.
47. Contin M, Riva R, Martinelli P, Albani F, Avoni P, Baruzzi A. Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther Drug Monit 2001;23(6):621–629.